 |
|
Assessment of the Protective Effect of Pneumococcal Vaccination in Preventing Meningitis After Cochlear Implantation
Benjamin P. C. Wei, MBBS, PhD;
Roy M. Robins-Browne, MB, BCh, PhD, FRCPath, FRCPA;
Robert K. Shepherd, PhD;
Kristy Azzopardi, BSc (Honours);
Graeme M. Clark, MBMS, PhD, FRCS(Edin), FRCS(Eng), FRACS;
Stephen J. O’Leary, MBBS, PhD, FRACS
Arch Otolaryngol Head Neck Surg. 2007;133(10):987-994.
Objectives To examine if a 23-valent pneumococcal capsular polysaccharide vaccine (PPV23) reduces the risk of meningitis in healthy rats after cochlear implantation.
Design Interventional animal study.
Interventions Thirty-six rats (18 immunized and 18 unimmunized) received cochlear implantations and were then infected with Streptococcus pneumoniae via 3 different routes (hematogenous, middle ear, and inner ear) in numbers sufficient to induce meningitis.
Results The rats with implants that received PPV23 were protected from meningitis when the bacteria were delivered via the hematogenous and middle-ear routes (Fisher exact test P < .05). However, the protective effect of the vaccine in the rats with implants was only moderate when the bacteria were inoculated directly into the inner ear.
Conclusions Our animal model clearly demonstrates that immunization can protect healthy rats with a cochlear implant from meningitis caused by a vaccine-covered serotype. This finding supports the notion that all current and future implant recipients should be vaccinated against S pneumoniae.
Author Affiliations: Bionic Ear Institute (Drs Wei, Shepherd, and Clark) and Departments of Otolaryngology (Drs Wei and O’Leary) and Microbiology and Immunology (Dr Robins-Browne and Ms Azzopardi), University of Melbourne, Melbourne, Victoria, Australia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
